ПЕРСПЕКТИВЫ ЛЕЧЕНИЯ БОЛЬНЫХ РАКОМ ТОЛСТОЙ КИШКИ С МУТАЦИЕЙ В ГЕНЕ BRAF

Обложка

Цитировать

Полный текст

Аннотация

Рак толстой кишки (РТК) представляет собой гетерогенную группу опухолей, отличающихся как механизмами канцерогенеза и, следовательно, молекулярными изменениями, так и прогнозом течения болезни и особенностями терапии. К настоящему времени в клинической практике уже необходимо оценивать статус генов KRAS и NRAS для определения возможности назначения анти-EGFR препаратов при метастатическом РТК. Обособленной группой больных с неблагоприятным течением болезни являются пациенты с мутацией в гене BRAF в опухоли. В данном обзоре мы сконцентрируемся на биологических особенностях РТК с мутацией в гене BRAF, эпидемиологии, клинических характеристиках болезни на разных стадиях, выборе терапии и перспективных направлениях лечения данной группы пациентов.

Об авторах

М. Ю. Федянин

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва

Автор, ответственный за переписку.
Email: fedianinmu@mail.ru
Россия

А. А. Трякин

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва

Email: fedianinmu@mail.ru
Россия

С. А. Тюляндин

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва

Email: fedianinmu@mail.ru
Россия

Список литературы

  1. Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21(14):2787–99.
  2. Mayer A., Takimoto M., Fritz E. et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71(8):2454–60.
  3. Custodio A., Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations. Crit Rev Oncol Hematol 2013;85(1):45–81.
  4. Di Fiore F., Blanchard F., Charbonnier F. et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166–9.
  5. Lievre A., Bachet J.B., Boige V. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374–9.
  6. Niault T.S., Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis 2010;31(7):1165–74.
  7. Guan K.L., Figueroa C., Brtva T.R. et al. Negative regulation of the serin/threonine kinase B-RAF by Akt. J Biol Chem 2000;275(35):27354–9.
  8. Roskoski R. Jr. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010;399(3):313–7.
  9. Pakneshan S., Salajegheh A., Smith R.A., Lam A.K. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013;45:346–56.
  10. Jones D.T., Kocialkowski S., Liu L. et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion inactivating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009;28(20):2119–23.
  11. Lawson A.R., Tatevossian R.G., Phipps K.P. et al. RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol 2010;120(2):271–3.
  12. Ogino S., Nosho K., Kirkner G.J. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58(1):90–6.
  13. Samowitz W.S., Sweeney C., Herrick J. et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65(14):6063–70.
  14. Barault L., Veyrie N., Jooste V. et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122(10):2255–9.
  15. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO: Classification of tumours of the digestive system, 4th ed. Lyon: IARC Press, 2010.
  16. Wang L., Cunningham J.M., Winters J.L. et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209–12.
  17. Roth A., Tejpar S., Delorenzi M. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2009;28:466–74.
  18. Roth A., Klingbiel D., Yan P. et al. Molecular and clinical determinants of survival following relapse after curative treatment of stage II–III colon cancer (CC): results of the translational study of PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2010;28(suppl; abstr 3504).
  19. Dienstmann R., Guinney J., Delorenzi M. et al. Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol 2014;32:5s (suppl; abstr 3511).
  20. Artale S., Sartore-Bianchi A., Veronese S.M. et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26(25):4217–9.
  21. Kopetz S., Overman M.J., Chen K. et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s (suppl; abstr 3509).
  22. Graham D.M., Arseneault M., Sukhai M.A. et al. Analysis of clonal evolution in colorectal cancer. J Clin Oncol 2014;32:5s (suppl; abstr 3510).
  23. Zlobec I., Bihl M.P., Schwarb H. et al. Clinicopathological and protein characterization of BRAF- and K-RASmutated colorectal cancer and implications for prognosis. Int J Cancer 2010;127(2): 367–80.
  24. Tie J., Gibbs P., Lipton L. et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer 2011;128:2075–84.
  25. Pinheiro M., Ahlquist T., Danielsen S.A. et al. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. BMC Cancer 2010;10:587.
  26. Bokemeyer C., Kohne C., Rougier P. et al. Cetuximab with chemotherapy (CT) as firstline treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol 2010;28(Suppl.) [abstract 3506].
  27. Hutchins G., Southward K., Handley K. et al. Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29:1261–70.
  28. Safaee Ardekani G., Jafarnejad S.M., Tan L., et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012;7(10):e47054.
  29. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609–18.
  30. Gavin P.G., Colangelo L.H., Fumagalli D. et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012;18(23):6531–41.
  31. Koopman M., Kortman G.A., Mekenkamp L. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266–73.
  32. Yuan Z.X., Wang X.Y., Qin Q.Y. et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a metaanalysis. PLoS One 2013;8(6):e65995. doi: 10.1371/journal.pone.0065995.
  33. Mao C., Liao R.Y., Qiu L.X. et al. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep 2011;38(4):2219–23.
  34. Xu Q., Xu A.T., Zhu M.M. et al. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a metaanalysis. J Dig Dis 2013;14(8):409–16.
  35. Bokemeyer C., Van Cutsem E., Rougier P. et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomized clinical trials. Eur J Cancer 2012;48:1466–75.
  36. Van Cutsem E., Kohne C.H., Lang L. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011–9. doi: 10.1200/JCO.2010.33.5091.
  37. Seymour M.T., Brown S.R., Richman S. et al. Addition of panitumumab to irinotecan: results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J Clin Oncol 2011;29 (Suppl.) [abstract 3523].
  38. Tol J., Dijkstra J.R., Klomp M. et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010;46:1997–2009.
  39. Di Nicolantonio F., Martini M., Molinari F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26(35):5705–12.
  40. De Roock W., Claes B., Bernasconi D. et al. Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11(8):753–62.
  41. Richman S.D., Seymour M.T., Chambers P. et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931–7.
  42. Hutchins G., Southward K., Handley K. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29:1261–70.
  43. Ogino S., Shima K., Meyerhardt J.A. et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890–900.
  44. Ince W.L., Jubb A.M., Holden S.N. et al. Association of k-ras, b-raf and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005;97(13):981–9.
  45. Loupakis F., Cremolini C., Salvatore L. et al. FOLFOXIRI plus bevacizumab as firstline treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014 Jan;50(1):57–63.
  46. Loupakis F., Cremolini C., Lonardi S. et al. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J Clin Oncol 2014;32:5s (suppl; abstr 3519).
  47. Kopetz S., Desai J., Chan E. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010;28(15 suppl). Abstr. 3534. 48. Liu L., Shi H., Bleam M.R. et al. Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models. J Clin Oncol 2014;32:5s (suppl; abstr 3513).
  48. Geel R.V., Elez E., Bendell J.C. et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 2014;32:5s (suppl; abstr 3514).
  49. Bendell J.C., Atreya C.E., Andrй T. et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 2014;32:5s (suppl; abstr 3515).
  50. Hong D.S., Morris V.K., Fu S. et al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 2014;32:5s (suppl; abstr 3516).
  51. Tabernero J., Chan E., Baselga J. et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). J Clin Oncol 2014;32:5s (suppl; abstr 3518).
  52. Corcoran R.B., Atreya C.E., Falchook G.S. et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. J Clin Oncol 2014;32:5s (suppl; abstr 3517).

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 85909 от  25.08.2023.